We look forward to additional progress in the federal Actos bladder cancer litigation as it prepares for bellwether trials early next year.
New York, New York (PRWEB) October 06, 2013
More than 2,500 Actos lawsuits (http://www.consumerinjurylawyers.com/actos/Actos-Lawsuit.html) filed on behalf of patients whose long-term use of the Type 2 diabetes medication allegedly caused bladder cancer are moving forward in the U.S. District Court, Western District of Louisiana, Bernstein Liebhard LLP reports. According to court records, the next Status Conference in the Actos bladder cancer litigation is scheduled for October 25, 2013. (In re: Actos Product Liability Litigation, MDL No. 2299)
“Our Firm receives regular Actos lawsuit inquiries from people who have allegedly developed bladder cancer due to their long-term use of Actos. We look forward to additional progress in the federal Actos bladder cancer litigation as it prepares for bellwether trials early next year,” says Bernstein Liebhard LLP, a nationwide law firm representing the victims of defective drugs and medical devices. The Firm is currently offering free Actos lawsuit evaluations to individuals who were diagnosed with bladder cancer following long-term use of the drug.
Actos Bladder Cancer Lawsuits
The litigation involving Actos bladder cancer allegations began to mount after the U.S. Food & Drug Administration (FDA) warned in June 2011 that use of the drug for a year or more could increase the risk of developing the potentially-deadly disease. According to court documents, all of the Actos lawsuits pending in the western district of Louisiana allege that Takeda Pharmaceuticals and other defendants concealed knowledge that Actos could increase a person’s chances of developing bladder cancer, and failed to provide adequate warnings about that risk to the public and medical community. The first Actos bladder lawsuit trials will begin in the federal litigation in January 2014.
Court records indicate that Actos lawsuits began going to trial at the state court level earlier this year. In April a Los Angeles Superior Court jury awarded $6.5 million to a plaintiff who was diagnosed with bladder after taking Actos for four years. However, the plaintiff has appealed a decision by the judge overseeing the case to grant Takeda Pharmaceuticals’ request to set aside the verdict. (Cooper v. Takeda Pharmaceuticals America Inc., CGC-12-518535, California Superior Court)
Last month, the nation’s second trial of an Actos bladder cancer claim concluded in Maryland State Court with $1.7 million being awarded to the family of a man who died of bladder cancer following long-term use of Actos. However, according to court records, the judge presiding over the trial tossed out the verdict in accordance with Maryland law because the jury also found that the decedent’s decades-long smoking habit contributed to the development of the disease. (An v. Nieberlein, 24-C12003565, Circuit Court for the City of Baltimore, State of Maryland.)
Actos patients who were diagnosed with bladder cancer following long-term use of the medication may be entitled to compensation for medical expenses, lost wages, pain and suffering, and more. Learn More about filing an Actos bladder cancer lawsuit by visiting Bernstein Liebhard LLP’s website. For additional information, please call 800-511-5092 today.
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the “Plaintiffs’ Hot List,” recognizing the top plaintiffs’ firms in the country, for the past 10 consecutive years.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2013 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Felecia L. Stern, Esq.
Bernstein Liebhard LLP